TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers linked lower levels of the protective protein NRF2 in oligodendrocytes to abnormal myelin and loss of large nerve fibers in people with faster cognitive decline. Mouse experiments showed that reducing NRF2 in these cells produced similar changes, but the findings do not establish a treatment for cognitive decline in people.
A study published in Nature Medicine links lower activity of the protective protein NRF2 in myelin-producing brain cells to nerve-fiber abnormalities and faster cognitive decline in older adults. Researchers from the University of Edinburgh and the UK Dementia Research Institute also found similar changes after reducing NRF2 in oligodendrocytes in mice, pointing to a possible biological target for future research—not a proven treatment for age-related decline.
The team examined data from the Lothian Birth Cohort 1936, whose participants had cognitive abilities tracked from childhood into old age. Between ages 70 and 82, participants were assessed in areas including memory, processing speed and spatial reasoning. Of 1,091 enrolled people, 866 completed additional cognitive testing after age 70; the rate of change varied among participants.
Researchers then examined brain tissue collected after death from a subset of the cohort. People who had experienced greater cognitive decline tended to have fewer large nerve fibers and an abnormal buildup of myelin, the insulating coating that helps electrical signals travel along nerve fibers. The tissue findings were associated with the pace of cognitive change, rather than simply a person’s test performance at one age.
The researchers focused on oligodendrocytes, cells that produce and maintain myelin. In people with more severe decline, these cells had lower levels of NRF2, which regulates genes involved in cellular defenses and normal function. In mice, specifically reducing NRF2 in oligodendrocytes led to excessive myelin, loss of large nerve fibers and weaker improvements in cognitive performance as the animals aged. The mouse results support a possible causal role for NRF2 disruption in those changes, but do not show that the same intervention would prevent decline in people.
A New Target in Aging Brain Cells
The findings challenge a simple view of oligodendrocytes as uniformly protective. The cells are needed to maintain myelin, but the study suggests that age-related dysfunction may alter that support and contribute to damage in nerve fibers. This offers researchers a potential way to investigate how changes in the brain’s insulation system relate to memory and thinking over time.
The work also raises the prospect of testing drugs that affect the NRF2 pathway. Medicines targeting this pathway are already used for other neurological conditions, including multiple sclerosis, according to the report. That existing clinical experience may inform future studies, but it does not establish that these medicines are safe or effective for older adults with cognitive decline. Any use for this purpose would require research and clinical testing.
As an affiliate, we earn on qualifying purchases.
From Long-Term Testing to Brain Tissue
The cohort’s value for this research lies in its long record of cognitive assessments, which began in childhood and continued into old age. That history allowed scientists to compare changes over decades with biological features seen in brain tissue later collected from some participants. The analysis therefore examined patterns associated with the rate of decline, rather than relying only on a single cognitive assessment.
Researchers combined that human evidence with experiments in mice. The human tissue linked lower oligodendrocyte NRF2 levels with more severe decline and abnormalities in myelin and nerve fibers; the animal experiments tested what happened when NRF2 was reduced in those cells. Together, the approaches strengthen the case for further study, while leaving open how closely the experimental changes represent the complex causes of cognitive decline in humans.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital, part of Unity Health Toronto
oligodendrocyte support supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Treatment Benefits Remain Unproven
The study does not show that low NRF2 activity is the sole cause of cognitive decline, or that increasing the protein would prevent or reverse it in people. The human findings are based on brain tissue from a subset of cohort members and show associations; the experiments that directly reduced NRF2 were conducted in mice.
It is also not clear which people might benefit from a drug affecting this pathway, what dose or treatment period could be appropriate, or what risks could arise in older adults. The report does not provide results from a clinical trial testing an NRF2-targeting medicine for age-related cognitive decline. The scale of any potential benefit remains unknown.
As an affiliate, we earn on qualifying purchases.
Testing the Pathway in People
Further research will need to establish how NRF2 changes in oligodendrocytes unfold with age and whether they contribute to cognitive decline in a way that can be altered safely. Researchers would also need to test whether medicines that affect the pathway improve cognitive outcomes in older adults, rather than assuming that results from multiple sclerosis or mouse studies apply to this population.
Until such studies report results, the work identifies a potential research target, not a recommended treatment. No timeline for clinical trials or a repurposed therapy is established in the supplied report.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are oligodendrocytes?
Oligodendrocytes are brain cells that produce and maintain myelin, the insulating layer around nerve fibers that supports the transmission of electrical signals.
What did researchers find in people?
In brain tissue from a subset of participants, greater cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower levels of NRF2 in oligodendrocytes. These are associations, not proof that NRF2 changes caused each person’s decline.
Did the study prove that an existing drug can prevent cognitive decline?
No. The report says the NRF2 pathway is targeted by drugs used for other conditions, but it does not describe a clinical trial showing that these medicines prevent or treat age-related cognitive decline.
Why did researchers use mice?
The mouse experiments let the team reduce NRF2 specifically in oligodendrocytes. The animals then developed myelin and nerve-fiber changes similar to those observed in human brain tissue, supporting further investigation. Mouse findings do not establish that the same effects or treatments will apply to people.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
